Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | FABP2 | P12104 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4340386 | 0.84 | AKR1C3 (0.50) | PTGS1PGRPDE4AAKR1C3AKR1C2 | |
| Nitric Acid SCHEMBL4339722 | 0.83 | PTGS1 (0.49) | PTGS1PGRPDE4AAKR1C3AKR1C2 | |
| SCHEMBL4333084 | 0.80 | PTGS1 (0.52) | PTGS1PGRPDE4AAKR1C3AKR1C2 | |
| SCHEMBL4435969 | 0.79 | TDP1 (0.47) | PTGS1AKR1C3AKR1C2LMNAPTGS2 | |
| SCHEMBL5498892 | 0.78 | FAAH (0.54) | PTGS1PGRPDE4AAKR1C3AKR1C2 | |
| SCHEMBL2722631 | 0.75 | PTGS1 (0.56) | PTGS1PGRPDE4AAKR1C3AKR1C2 | |
| SCHEMBL5605512 | 0.75 | PTGS1 (0.56) | PTGS1PGRPDE4AAKR1C3AKR1C2 | |
| SCHEMBL29380153 | 0.75 | PTGS1 (0.56) | PTGS1PGRPDE4AAKR1C3AKR1C2 | |
| SCHEMBL135465 | 0.75 | PTGS1 (0.56) | PTGS1PGRPDE4AAKR1C3AKR1C2 | |
| SCHEMBL12103285 | 0.73 | PTGS1 (0.53) | PTGS1PGRPDE4AAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1526839-B1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX SA (FR) | 2007-03-14 | — | — | EP | claimed |
| US-20070010458-A1 | Drugs for the arthritis treatment | NICOX S.A. (FR) | 2007-01-11 | — | — | US | claimed |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | NICOX S.A. (FR) | 2006-08-03 | — | — | US | claimed |
| EP-1492543-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | Nicox S.A. (FR) | 2005-01-05 | — | — | EP | claimed |
| WO-2004000300-A1 | CYCLOOXYGENASE-2 INHIBITORS | NICOX S.A. (FR) | 2003-12-31 | — | — | WO | claimed |
| WO-2003084550-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | NICOX S.A. (FR) | 2003-10-16 | — | — | WO | claimed |
| EP-1526839-B1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX SA (FR) | 2007-03-14 | — | — | EP | disclosed |
| US-20070010458-A1 | Drugs for the arthritis treatment | NICOX S.A. (FR) | 2007-01-11 | — | — | US | disclosed |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | NICOX S.A. (FR) | 2006-08-03 | — | — | US | disclosed |
| EP-1492543-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | Nicox S.A. (FR) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084550-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | NICOX S.A. (FR) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | ABCG2, SLCO1B1, SLCO4C1 | PTGS1 515/4885PGR 894/4885PDE4A 1003/4885 |
| US-20070010458-A1 | Drugs for the arthritis treatment | PTGS1, ADORA2B, PTGS2 | PTGS1 1/4885PGR 2061/4885PDE4A 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.